Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties, primarily used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS). It acts as a GABAergic modulator.
## Primary Indications
* Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose by 5-10 mg every 3 days to a maximum of 20 mg twice daily, based on clinical response and tolerability.
* **Maintenance:** Typically 10-20 mg twice daily.
* **Maximum Dose:** 20 mg twice daily (40 mg/day).
## Pediatric Dosing
* **For patients 2 years of age and older:**
* **Initiation:** 5 mg once daily.
* **Titration:** Increase dose by 2.5-5 mg every 3 days to a maximum of 10 mg twice daily, based on clinical response and tolerability.
* **Maintenance:** Typically 5-10 mg twice daily.
* **Maximum Dose:** 10 mg twice daily (20 mg/day).
* **For patients younger than 2 years of age:** Dosing is not established due to safety concerns and lack of data.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment guidelines are established, but initiation at the lower end of the dosing range and slow titration are recommended.
* **Renal Impairment:** No specific dose adjustment is recommended, but use with caution.
* **Concomitant Medications:** Dose may need adjustment when used with strong CYP3A4 inhibitors or inducers, or other CNS depressants.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Somnolence, fatigue, drooling, constipation, decreased appetite, aggression, irritability, dizziness, gait disturbance, upper respiratory tract infection, vomiting.
* **Serious:** Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior or ideation, withdrawal symptoms (especially with abrupt discontinuation), respiratory depression, dependence, abuse.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of sedation, respiratory depression, and coma.
* **CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir):** May increase clobazam plasma concentrations, increasing the risk of adverse effects.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine):** May decrease clobazam plasma concentrations, potentially reducing efficacy.
* **Stimulants (e.g., amphetamines):** Clobazam may reduce the efficacy of stimulants.
## Monitoring
* Monitor for efficacy (seizure frequency).
* Monitor for adverse effects, particularly somnolence, behavioral changes, and signs of withdrawal.
* Assess for signs of drug abuse or dependence.
* Monitor for suicidal behavior or ideation.
* Monitor for severe skin reactions.
## Clinical Pearls
* Clobazam should be initiated at a low dose and gradually titrated to minimize adverse effects.
* Avoid abrupt discontinuation due to potential for withdrawal symptoms. Tapering is recommended.
* Clobazam can cause significant somnolence; advise patients to use caution when performing activities requiring mental alertness.
* The risk of severe skin reactions is a serious concern; patients should be advised to seek immediate medical attention if rash develops.
* Due to the risk of dependence and abuse, clobazam should be prescribed for the shortest duration necessary.
***
*Please verify the current prescribing information for the most up-to-date and comprehensive drug information.*
